Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Valneva ( (VALN) ) just unveiled an update.
On July 11, 2025, Valneva announced that the European Medicines Agency (EMA) lifted the temporary restriction on the use of its chikungunya vaccine, IXCHIQ®, for people aged 65 and above. This decision follows a comprehensive review by EMA’s safety committee, which found that while serious side effects occurred mainly in older individuals, the vaccine effectively triggers antibody production against the chikungunya virus. This development is significant for Valneva as it enhances the vaccine’s marketability and potential impact on public health, particularly for older adults at increased risk of severe chikungunya disease.
The most recent analyst rating on (VALN) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.
Spark’s Take on VALN Stock
According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.
The overall stock score of 47 reflects significant financial and valuation challenges, despite some operational achievements and revenue growth. The most impactful factors include the ongoing financial losses and negative cash flow, compounded by a negative P/E ratio. Technical indicators suggest limited momentum, and earnings call insights present mixed sentiment with both significant progress and notable challenges.
To see Spark’s full report on VALN stock, click here.
More about Valneva
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company focuses on providing first-, best-, or only-in-class vaccine solutions and has a strong track record of advancing multiple vaccines from early R&D to approvals. Valneva currently markets three proprietary travel vaccines and is working on vaccine candidates for Lyme disease, Shigella, Zika virus, and other global public health threats.
Average Trading Volume: 37,384
Technical Sentiment Signal: Sell
Current Market Cap: $480.1M
For detailed information about VALN stock, go to TipRanks’ Stock Analysis page.